BIIB stock forecast, quote, news & analysis
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases... Show more
Why Biogen Inc. (BIIB) Stock Is Up +10.5% in the Last 30 Days
Key Takeaways
- Biogen Inc. (BIIB) shares rose approximately 10.5% over the 30 days ending June 29, 2026, climbing from a May 29 close of 196.00 to 216.63.
- The stock reached a new 52-week high of 219.72 during the period amid positive pipeline and M&A developments.
- Key drivers included a $1 billion acquisition of RayThera and FDA breakthrough therapy designation for salanersen.
- Broader quarterly performance showed strong year-to-date gains of 21.58% as of late June 2026.
- Analysts maintain a Buy rating with an average price target of 220.28, reflecting measured optimism on new franchises.
Biogen Inc. (BIIB) Company Overview and Market Position
Biogen Inc. discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Its portfolio includes established multiple sclerosis treatments such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI, along with SPINRAZA for spinal muscular atrophy and newer offerings like LEQEMBI for Alzheimer’s disease, SKYCLARYS for Friedreich’s ataxia, and ZURZUVAE for postpartum depression. The company also markets biosimilars and collaborates on oncology and other therapies. Headquartered in Cambridge, Massachusetts, Biogen competes in the drug manufacturers-general sector with a focus on high-value neurological indications.
Biogen Inc. (BIIB) Stock Price Performance: Last 30 Days vs. Quarter
From the May 29, 2026 close of 196.00 to the June 29, 2026 close of 216.63, BIIB advanced 10.5%. The move lifted the stock to a 52-week high of 219.72. Over the broader quarter, the shares posted a year-to-date return of 21.58% through late June 2026, outpacing the S&P 500’s 9.23% gain in the same window. Trading volume remained elevated on several sessions as the price tested new highs.
What Drove BIIB Stock Price in the Last 30 Days
Positive clinical and corporate developments supported the advance. The company announced a $1 billion acquisition of RayThera and received FDA breakthrough therapy designation for salanersen. These updates coincided with the stock reaching 52-week highs. Additional coverage highlighted Biogen’s Alzheimer’s portfolio and Phase 2 data presentations planned for upcoming medical meetings. Sector rotation into large-cap biopharma names and improving sentiment around pipeline diversification also contributed to buying interest.
What Drove BIIB Stock Performance Over the Last Quarter
Over the first half of 2026, Biogen benefited from continued execution on newer product launches, including LEQEMBI and SKYCLARYS, while legacy multiple sclerosis revenue remained a stable contributor. The company trimmed certain R&D programs following the Apellis transaction and focused resources on high-potential neurology assets. Macroeconomic stability and selective institutional positioning in healthcare further supported the multi-month uptrend that culminated in the recent 30-day surge.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s top-performing AI trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the highest-ranked and most relevant bots appear in this section based on recent performance metrics. Bots differ by strategy, time horizon, and risk parameters. Investors can review detailed statistics and backtest results directly on the platform.
BIIB Stock Forecast Drivers: What Investors Should Watch Next
Key items for monitoring include the July 29, 2026 earnings release, updates on LEQEMBI adoption and reimbursement, progress on additional pipeline candidates such as diranersen, and any further regulatory decisions. Macroeconomic factors, competitive dynamics in Alzheimer’s and neuromuscular disease markets, and potential partnership announcements will also influence sentiment. Analyst expectations remain centered on sustainable revenue diversification beyond legacy products.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsBIIB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on June 25, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on BIIB as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 179 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIIB broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.581) is normal, around the industry mean (19.576). P/E Ratio (21.474) is within average values for comparable stocks, (26.499). Projected Growth (PEG Ratio) (3.941) is also within normal values, averaging (4.388). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (2.966) is also within normal values, averaging (3.942).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor